Header Logo

Connection

Renate Strehlau to Child, Preschool

This is a "connection" page, showing publications Renate Strehlau has written about Child, Preschool.
Connection Strength

1,289
  1. A description of early neurodevelopment in a cohort of HIV-exposed uninfected children. AIDS Care. 2020 11; 32(11):1421-1428.
    View in: PubMed
    Score: 0,121
  2. Substituting Abacavir for Stavudine in Children Who Are Virally Suppressed Without Lipodystrophy: Randomized Clinical Trial in Johannesburg, South Africa. J Pediatric Infect Dis Soc. 2018 Aug 17; 7(3):e70-e77.
    View in: PubMed
    Score: 0,109
  3. HIV-associated neurodevelopmental delay: prevalence, predictors and persistence in relation to antiretroviral therapy initiation and viral suppression. Child Care Health Dev. 2016 11; 42(6):881-889.
    View in: PubMed
    Score: 0,095
  4. Developmental status of preschool children receiving cART: a descriptive cohort study. Child Care Health Dev. 2016 May; 42(3):410-4.
    View in: PubMed
    Score: 0,091
  5. PRINCE-1: safety and efficacy of atazanavir powder and ritonavir liquid in HIV-1-infected antiretroviral-naïve and -experienced infants and children aged =3 months to <6 years. J Int AIDS Soc. 2015; 18:19467.
    View in: PubMed
    Score: 0,087
  6. Lipid profiles in young HIV-infected children initiating and changing antiretroviral therapy. J Acquir Immune Defic Syndr. 2012 Aug 01; 60(4):369-76.
    View in: PubMed
    Score: 0,072
  7. Absence seizures associated with efavirenz initiation. Pediatr Infect Dis J. 2011 Nov; 30(11):1001-3.
    View in: PubMed
    Score: 0,068
  8. Pharmacokinetics, safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in children with HIV aged from 2 years and weighing at least 14 kg. J Int AIDS Soc. 2025 Feb; 28(2):e26414.
    View in: PubMed
    Score: 0,043
  9. Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study. Lancet HIV. 2024 May; 11(5):e300-e308.
    View in: PubMed
    Score: 0,040
  10. Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir. Antimicrob Agents Chemother. 2020 04 21; 64(5).
    View in: PubMed
    Score: 0,031
  11. Bone Quality Measured Using Calcaneal Quantitative Ultrasonography Is Reduced Among Children with HIV in Johannesburg, South Africa. J Pediatr. 2019 12; 215:267-271.e2.
    View in: PubMed
    Score: 0,029
  12. Distinct epigenetic profiles in children with perinatally-acquired HIV on antiretroviral therapy. Sci Rep. 2019 07 19; 9(1):10495.
    View in: PubMed
    Score: 0,029
  13. Mitochondrial Impairment in Well-Suppressed Children with Perinatal HIV-Infection on Antiretroviral Therapy. AIDS Res Hum Retroviruses. 2020 01; 36(1):27-38.
    View in: PubMed
    Score: 0,029
  14. Biomarkers of Aging in HIV-Infected Children on Suppressive Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2018 08 15; 78(5):549-556.
    View in: PubMed
    Score: 0,027
  15. Patterns of Growth, Body Composition, and Lipid Profiles in a South African Cohort of Human Immunodeficiency Virus-Infected and Uninfected Children: A Cross-Sectional Study. J Pediatric Infect Dis Soc. 2018 May 15; 7(2):143-150.
    View in: PubMed
    Score: 0,027
  16. Age at antiretroviral therapy initiation and cell-associated HIV-1 DNA levels in HIV-1-infected children. PLoS One. 2018; 13(4):e0195514.
    View in: PubMed
    Score: 0,027
  17. Decreased bone turnover in HIV-infected children on antiretroviral therapy. Arch Osteoporos. 2018 Apr 05; 13(1):40.
    View in: PubMed
    Score: 0,027
  18. Dietary Inadequacies in HIV-infected and Uninfected School-aged Children in Johannesburg, South Africa. J Pediatr Gastroenterol Nutr. 2017 09; 65(3):332-337.
    View in: PubMed
    Score: 0,025
  19. Switching to Efavirenz Versus Remaining on Ritonavir-boosted Lopinavir in Human Immunodeficiency Virus-infected Children Exposed to Nevirapine: Long-term Outcomes of a Randomized Trial. Clin Infect Dis. 2017 Aug 01; 65(3):477-485.
    View in: PubMed
    Score: 0,025
  20. Effect of Lopinavir and Nevirapine Concentrations on Viral Outcomes in Protease Inhibitor-experienced HIV-infected Children. Pediatr Infect Dis J. 2016 12; 35(12):e378-e383.
    View in: PubMed
    Score: 0,024
  21. Unusually High Calcaneal Speed of Sound Measurements in Children with Small Foot Size. Ultrasound Med Biol. 2017 01; 43(1):357-361.
    View in: PubMed
    Score: 0,024
  22. Extent of disclosure: what perinatally HIV-infected children have been told about their own HIV status. AIDS Care. 2017 03; 29(3):378-386.
    View in: PubMed
    Score: 0,024
  23. Decreased Vigorous Physical Activity in School-Aged Children with Human Immunodeficiency Virus in Johannesburg, South Africa. J Pediatr. 2016 05; 172:103-9.
    View in: PubMed
    Score: 0,023
  24. Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation. BMC Infect Dis. 2016 Feb 02; 16:56.
    View in: PubMed
    Score: 0,023
  25. Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial. JAMA. 2015 Nov 03; 314(17):1808-17.
    View in: PubMed
    Score: 0,022
  26. Young age at start of antiretroviral therapy and negative HIV antibody results in HIV-infected children when suppressed. AIDS. 2015 Jun 01; 29(9):1053-60.
    View in: PubMed
    Score: 0,022
  27. Plasma lopinavir concentrations predict virological failure in a cohort of South African children initiating a protease-inhibitor-based regimen. Antivir Ther. 2014; 19(4):399-406.
    View in: PubMed
    Score: 0,020
  28. Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment. BMC Pediatr. 2014 Feb 12; 14:39.
    View in: PubMed
    Score: 0,020
  29. Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children. Pediatr Infect Dis J. 2013 Aug; 32(8):851-5.
    View in: PubMed
    Score: 0,019
  30. Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy. Arch Dis Child. 2013 Apr; 98(4):258-64.
    View in: PubMed
    Score: 0,018
  31. Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. Lancet Infect Dis. 2012 Jul; 12(7):521-30.
    View in: PubMed
    Score: 0,017
  32. Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children. Clin Infect Dis. 2011 Feb 15; 52(4):514-21.
    View in: PubMed
    Score: 0,016
  33. Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis. J Infect Dis. 2010 Apr 15; 201(8):1121-31.
    View in: PubMed
    Score: 0,015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.